Thank you, Madam Chairperson.
Thanks to all of you for your presentations.
I want to touch a bit on the off-label question and the whole area of what I would see as a problem, and that is the involvement of the industry throughout the process of post-market surveillance.
There have been concerns raised about the government's new direction around risk management and the progressive licensing system as it relates partly to the off-label issue. That is, it might actually lead to a fairly rapid approval of already approved drugs for new indications without that company having to go through the rigour of the clinical trials and the surveillance and full disclosure before an old drug just gets automatically licensed for new indications.
Is that not a problem, from any of your points of view?